{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:06:43Z","timestamp":1789873603740,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jsat.2021.108546","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:32:24Z","timestamp":1624519944000},"page":"108546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration"],"prefix":"10.1016","volume":"131","author":[{"given":"Stephen","family":"Crystal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Nowels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Samples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Robinson","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Treitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jsat.2021.108546_bb0005","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/hec.3944","article-title":"Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin","volume":"28","author":"Beheshti","year":"2019","journal-title":"Health Economics"},{"key":"10.1016\/j.jsat.2021.108546_bb0010","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jsat.2021.108546_bb0015","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jsat.2021.108546_bb0020","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jsat.2021.108546_bb0025","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"5","key":"10.1016\/j.jsat.2021.108546_bb0030","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine-naloxone therapy in pain management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jsat.2021.108546_bb0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2021.108546_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2017.10.001","article-title":"Experiences of three states implementing the Medicaid health home model to address opioid use disorder - Case studies in Maryland, Rhode Island, and Vermont","volume":"83","author":"Clemans-Cope","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2021.108546_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"6","key":"10.1016\/j.jsat.2021.108546_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/L15-0524","article-title":"The integration of care for mental health, substance abuse, and other behavioral health conditions into primary care","volume":"164","author":"Crowley","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108546_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jpain.2015.12.006","article-title":"Risk factors of prescription opioid overdose among Colorado Medicaid beneficiaries","volume":"17","author":"Dilokthornsakul","year":"2016","journal-title":"The Journal of Pain"},{"issue":"9","key":"10.1016\/j.jsat.2021.108546_bb0060","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011-2016","volume":"67","author":"Hedegaard","year":"2018","journal-title":"National Vital Statistics Reports"},{"key":"10.1016\/j.jsat.2021.108546_bb0065","series-title":"Integration of behavioral and physical health care: Licensing and reimbursement barriers and opportunities in New Jersey","author":"Jacobi","year":"2016"},{"key":"10.1016\/j.jsat.2021.108546_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/epirev\/mxaa011","article-title":"The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms","author":"Jones","year":"2020","journal-title":"Epidemiologic Reviews"},{"key":"10.1016\/j.jsat.2021.108546_bb0075","doi-asserted-by":"crossref","first-page":"102408","DOI":"10.1016\/j.jhealeco.2020.102408","article-title":"Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences","volume":"75","author":"Kim","year":"2021","journal-title":"Journal of Health Economics"},{"issue":"2","key":"10.1016\/j.jsat.2021.108546_bb0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jgs.16911","article-title":"Opioid prescribing in the 2016 Medicare fee-for-service population","volume":"69","author":"Maciejewski","year":"2021","journal-title":"Journal of the American Geriatrics Society"},{"issue":"7","key":"10.1016\/j.jsat.2021.108546_bb0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MLR.0000000000001340","article-title":"Discussing drug use with health care providers is associated with perceived need and receipt of drug treatment among adults in the United States","volume":"58","author":"Mauro","year":"2020","journal-title":"Medical Care"},{"issue":"2","key":"10.1016\/j.jsat.2021.108546_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10488-012-0449-1","article-title":"Dual diagnosis capability in mental health and addiction treatment services: An assessment of programs across multiple state systems","volume":"41","author":"McGovern","year":"2014","journal-title":"Administration and Policy in Mental Health"},{"key":"10.1016\/j.jsat.2021.108546_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jsat.2020.01.017","article-title":"Opioid overdose and inpatient care for substance use disorder care in Massachusetts","volume":"112","author":"Morgan","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108546_bb0100","series-title":"Designing Medicaid health homes for individuals with opioid dependency: Considerations for states","author":"Moses","year":"2015"},{"key":"10.1016\/j.jsat.2021.108546_bb0105","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"10.1016\/j.jsat.2021.108546_bb0110","author":"National Forensic Laboratory Information System (NFLIS)"},{"key":"10.1016\/j.jsat.2021.108546_bb0115","author":"New Jersey Division of Mental Health and Addiction Services (NJDMHAS)"},{"key":"10.1016\/j.jsat.2021.108546_bb0120","author":"New Jersey Office of the Governor"},{"key":"10.1016\/j.jsat.2021.108546_bb0125","author":"NJ Office of the Attorney General (NJOAG)"},{"key":"10.1016\/j.jsat.2021.108546_bb0130","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.drugalcdep.2021.108555","article-title":"Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders","volume":"221","author":"O\u2019Brien","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2021.108546_bb0135","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamapsychiatry.2018.1471","article-title":"Causes of death after nonfatal opioid overdose","volume":"75","author":"Olfson","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2021.108546_bb0140","series-title":"The future of fentanyl and other synthetic opioids","author":"Pardo","year":"2019"},{"key":"10.1016\/j.jsat.2021.108546_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/pm\/pnab058","article-title":"Impact of current pain status on low-barrier buprenorphine treatment response among patients with opioid use disorder","author":"Peck","year":"2021","journal-title":"Pain Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2021.108546_bb0150","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.pain.2013.05.004","article-title":"Buprenorphine\/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone","volume":"154","author":"Roux","year":"2013","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.jsat.2021.108546_bb0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.jsat.2021.108546_bb0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jad.2020.09.089","article-title":"Depression and buprenorphine treatment in patients with non-cancer pain and prescription opioid dependence without comorbid substance use disorders","volume":"278","author":"Scherrer","year":"2021","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1016\/j.jsat.2021.108546_bb0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.prcp.20180006","article-title":"Pharmacological and behavioral treatment of opioid use disorder","volume":"1","author":"Sofuoglu","year":"2019","journal-title":"Psychiatric Research and Clinical Practice"},{"issue":"3","key":"10.1016\/j.jsat.2021.108546_bb0170","first-page":"1","article-title":"Drug overdose deaths involving fentanyl, 2011-2016","volume":"68","author":"Spencer","year":"2019","journal-title":"National Vital Statistics Reports"},{"key":"10.1016\/j.jsat.2021.108546_bb0175","author":"Stewart"},{"issue":"Suppl. 2","key":"10.1016\/j.jsat.2021.108546_bb0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/add.12904","article-title":"Death matters: Understanding heroin\/opiate overdose risk and testing potential to prevent deaths","volume":"110","author":"Strang","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108546_bb0185","doi-asserted-by":"crossref","first-page":"108263","DOI":"10.1016\/j.jsat.2020.108263","article-title":"Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder","volume":"123","author":"Stringer","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108546_bb0190","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2021.108546_bb0195","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"issue":"10","key":"10.1016\/j.jsat.2021.108546_bb0200","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1377\/hlthaff.2017.0260","article-title":"Opioid abuse and poisoning: Trends in inpatient and emergency department discharges","volume":"36","author":"Tedesco","year":"2017","journal-title":"Health Affairs (Project Hope)"},{"issue":"22","key":"10.1016\/j.jsat.2021.108546_bb0205","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.2020.8020","article-title":"Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement","volume":"323","author":"U.S. Preventive Services Task Force (USPTF)","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108546_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugpo.2017.06.003","article-title":"US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations","volume":"46","author":"Unick","year":"2017","journal-title":"The International Journal on Drug Policy"},{"issue":"2","key":"10.1016\/j.jsat.2021.108546_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2021.108546_bb0220","series-title":"ICD-10: International classification of diseases and related health problems, 10th revision","author":"World Health Organization","year":"2015"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:57:18Z","timestamp":1760039838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"alternative-id":["S0740547221002725"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108546","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108546"}}